Quince Therapeutics

About Quince Therapeutics

Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Their focus includes developing therapies for rare pediatric neurodegenerative diseases such as Ataxia-Telangiectasia (A-T).

Products & Services

eDSP:A Phase 3 lead asset for the treatment of Ataxia-Telangiectasia (A-T), leveraging the proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform. It encapsulates dexamethasone sodium phosphate in a patient's own red blood cells to reduce adverse effects of corticosteroids while maintaining efficacy.

AIDE Technology Platform:An innovative drug/device combination that uses an automated process to encapsulate drugs into a patient's own red blood cells, enhancing tolerability, tissue biodistribution, reducing immunogenicity, and prolonging circulating half-life.

Specialties

Rare Pediatric Neurodegenerative Diseases Autologous Intracellular Drug Encapsulation (AIDE) Technology Treatment of Ataxia-Telangiectasia (A-T)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 22000000 MR: - FA: Up to $22 million FAN: 22000000	D: 2025-06-18 FD: 2025-06-18	3 investors
2	RT: Private Placement T: - FT: Private Placement	A: 11500000 MR: - FA: $11.5 million upfront, with up to an additional $10.4 million FAN: 11500000	D: 2025-06-12 FD: 2025-06-12	3 investors

Private Placement Latest

2025-06-18

$22.0M

3 investors (Pro only)

Private Placement 2025-06-12

$11.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dirk Thye

Chief Executive Officer, Chief Medical Officer, and Board Member

C

Charles Ryan

President

B

Brendan Hannah

Chief Operating Officer & Chief Business Officer

G

Giovanni Mambrini

Chief Technology Officer

P

Pamela Williamson

Head of Regulatory Affairs

M

Maureen Roden

Vice President, Clinical Development

View 23 more team members with Pro

Unlock Full Team Directory

Recent News